Bryan Holman
Optometrist · Millbrook, ALNPI 1225285083
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.2%), speaking fees and entertainment — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Coopervision Inc. at 47.4% of the total. Reporting peaked in 2019 at $3,331 and has fallen 85.0% since, to $498 in 2025. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $47.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$4K
- Optos, Inc.$2K
- Bausch & Lomb Americas Inc.$657
- Bausch & Lomb, A Division Of Bausch Health US, LLC$610
- Alcon$435
- Kala Pharmaceuticals, Inc.$349
- plus $835 from 12 others
What the payments were for
- Speaking & faculty fees$3,15037%
- Food & beverage$3,97647%
- Gifts$190%
- Entertainment$1,28315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 52 | $3,996 |
| Optos, Inc. | 19 | $1,546 |
| Bausch & Lomb Americas Inc. | 19 | $657 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 33 | $610 |
| Alcon | 13 | $435 |
| Kala Pharmaceuticals, Inc. | 11 | $349 |
| LKC Technologies, Inc. | 3 | $147 |
| AbbVie | 3 | $136 |
| Novartis | 8 | $126 |
| Tarsus Pharmaceuticals, Inc. | 5 | $99 |
| Maculogix, Inc. | 3 | $88 |
| Shire North American Group Inc | 1 | $66 |
| Topcon Healthcare, Inc. | 1 | $47 |
| Sun Pharmaceutical Industries Inc. | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $23 |
| Alcon Research LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clariti Contact Lens$3,100
- PANORAMIC OPHTHALMOSCOPE$957
- OCT OPHTHALMOSCOPE$957
- NFC-700$478
- INFUSE$360
- P200DTx$134
- P200T$134
- P200TE$134
- P200TxE$134
- TOTAL30$124
- MIEBO$113
- MyDay Contact Lens$112
- RESTASIS$110
How this compares
$8,428 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 72 | $29,067 |
| LumiganBimatoprost | 55 | $28,564 |
| RestasisCyclosporine | 22 | $22,156 |
| XiidraLifitegrast | 28 | $21,813 |
| MieboPerfluorohexyloctane/Pf | 12 | $16,309 |
| Loteprednol Etabonate | 29 | $5,667 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $5,010 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $4,329 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $3,704 |
| Latanoprost | 372 | $3,356 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 113 | $2,269 |
| Brimonidine Tartrate | 36 | $2,148 |
| Timolol Maleate | 46 | $805 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $652 |
| Prednisolone Acetate | 14 | $592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $657 | $67,189112 claims |
| AbbVieLumigan, Restasis, Combigan | $136 | $54,42490 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $610 | $5,66729 claims |
| AlconSimbrinza | $435 | $4,32919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Millbrook
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
- Benjamin KachelmanFlorence$101K
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Jack SchaefferHoover$60K
- Leo SemesBirmingham$60K
- Brooke KaplanMountain Brk$54K
- Patricia FulmerHuntsville$45K
- David SchaefferHoover$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.